EA015922B1 - ВВЕДЕНИЕ ИНГИБИТОРА mTOR ДЛЯ ЛЕЧЕНИЯ ПАЦИЕНТОВ СО ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛЬЮ - Google Patents

ВВЕДЕНИЕ ИНГИБИТОРА mTOR ДЛЯ ЛЕЧЕНИЯ ПАЦИЕНТОВ СО ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛЬЮ Download PDF

Info

Publication number
EA015922B1
EA015922B1 EA200801309A EA200801309A EA015922B1 EA 015922 B1 EA015922 B1 EA 015922B1 EA 200801309 A EA200801309 A EA 200801309A EA 200801309 A EA200801309 A EA 200801309A EA 015922 B1 EA015922 B1 EA 015922B1
Authority
EA
Eurasian Patent Office
Prior art keywords
cancer
administration
treatment
administered
patients
Prior art date
Application number
EA200801309A
Other languages
English (en)
Russian (ru)
Other versions
EA200801309A1 (ru
Inventor
Кэмилл Л. Бедроужн
Original Assignee
Ариад Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ариад Фармасьютикалз, Инк. filed Critical Ариад Фармасьютикалз, Инк.
Publication of EA200801309A1 publication Critical patent/EA200801309A1/xx
Publication of EA015922B1 publication Critical patent/EA015922B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EA200801309A 2005-11-14 2006-11-14 ВВЕДЕНИЕ ИНГИБИТОРА mTOR ДЛЯ ЛЕЧЕНИЯ ПАЦИЕНТОВ СО ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛЬЮ EA015922B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73676305P 2005-11-14 2005-11-14
PCT/US2006/044146 WO2007059106A2 (en) 2005-11-14 2006-11-14 Administration of mntor inhibitor to treat patients with cancer

Publications (2)

Publication Number Publication Date
EA200801309A1 EA200801309A1 (ru) 2008-10-30
EA015922B1 true EA015922B1 (ru) 2011-12-30

Family

ID=38049229

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200801309A EA015922B1 (ru) 2005-11-14 2006-11-14 ВВЕДЕНИЕ ИНГИБИТОРА mTOR ДЛЯ ЛЕЧЕНИЯ ПАЦИЕНТОВ СО ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛЬЮ

Country Status (9)

Country Link
US (1) US20070185150A1 (enExample)
EP (2) EP2662082A1 (enExample)
JP (2) JP5709354B2 (enExample)
CN (2) CN102579467A (enExample)
AU (1) AU2006315512B2 (enExample)
CA (1) CA2629714A1 (enExample)
EA (1) EA015922B1 (enExample)
IL (1) IL191356A0 (enExample)
WO (1) WO2007059106A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008016633A2 (en) * 2006-08-02 2008-02-07 Ariad Gene Therapeutics, Inc. Combination therapy
CA2669415A1 (en) * 2006-11-14 2008-05-22 Ariad Pharmaceuticals, Inc. Solid dosage form comprising ap23573
EP2278966B1 (en) 2008-03-21 2019-10-09 The University of Chicago Treatment with opioid antagonists and mtor inhibitors
PT2365802T (pt) 2008-11-11 2017-11-14 Univ Texas Microcápsulas de rapamicina e utilização para o tratamento de cancro
CA2758297A1 (en) 2009-04-16 2010-10-21 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
US8911766B2 (en) * 2009-06-26 2014-12-16 Abbott Cardiovascular Systems Inc. Drug delivery compositions including nanoshells for triggered drug release
EP2470179B1 (en) * 2009-08-26 2017-11-29 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Sustained release delivery systems for the prevention and treatment of head and neck cancers
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
KR101830455B1 (ko) * 2010-04-13 2018-02-20 노파르티스 아게 시클린 의존성 키나제 ４ 또는 시클린 의존성 키나제 （ｃｄｋ４／６） 억제제 및 ｍｔｏｒ 억제제를 포함하는 암 치료를 위한 조합물
JP2012061053A (ja) 2010-09-14 2012-03-29 Yuuki Kitaoka 投薬装置、投薬装置の作動方法及び投薬方法
AR083267A1 (es) * 2010-10-04 2013-02-13 Novartis Ag Combinaciones farmaceuticas
US20140066474A1 (en) * 2011-04-25 2014-03-06 Novartis Ag Combination of phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor
US9403829B2 (en) * 2011-12-02 2016-08-02 Signal Pharmaceuticals, Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1H)-one, a solid form thereof and methods of their use
SG11201406550QA (en) 2012-05-16 2014-11-27 Novartis Ag Dosage regimen for a pi-3 kinase inhibitor
WO2014078522A1 (en) 2012-11-14 2014-05-22 Ohio State Innovation Foundation Materials and methods useful for treating glioblastoma
WO2014160328A1 (en) 2013-03-13 2014-10-02 The Board Of Regents Of The University Of Texas System Mtor inhibitors for prevention of intestinal polyp growth
CN104721158B (zh) * 2013-12-24 2018-01-30 正大天晴药业集团股份有限公司 一种稳定的依维莫司片剂
AU2014373683B2 (en) 2013-12-31 2020-05-07 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
CN106166296A (zh) * 2016-07-01 2016-11-30 江南大学 一种辅助雷帕霉素治疗多种肿瘤的药物组合物
CN107714719A (zh) * 2017-11-08 2018-02-23 上海市第妇婴保健院 雷帕霉素在制备治疗白细胞介素‑27低表达子宫内膜癌的药物中的应用
CN115135322A (zh) 2020-02-21 2022-09-30 韩国高等科学技术学院 包含哺乳动物雷帕霉素靶蛋白信号传导抑制剂作为有效成分的用于预防或治疗癌症的药物组合物
CN114767867A (zh) * 2021-12-22 2022-07-22 中山大学孙逸仙纪念医院 一种用于治疗cdk4/6抑制剂耐药后的乳腺癌的药物组合物及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080975A1 (en) * 2001-04-06 2002-10-17 Wyeth Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil
US20050119288A1 (en) * 2003-08-18 2005-06-02 Pfizer Inc Dosing schedule for a novel anticancer agent
WO2006039414A2 (en) * 2004-09-30 2006-04-13 Ariad Gene Therapeutics, Inc. Treatment method
US20060183766A1 (en) * 2005-02-15 2006-08-17 Wyeth Orally bioavailable CCI-779 formulations
US20070105887A1 (en) * 2005-11-04 2007-05-10 Wyeth Antineoplastic combinations of temsirolimus and sunitinib malate

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206018A (en) 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US5378696A (en) * 1990-09-19 1995-01-03 American Home Products Corporation Rapamycin esters
US5078999A (en) 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5080899A (en) 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5321009A (en) 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
SG43072A1 (en) 1991-06-18 1997-10-17 American Home Prod Method of treating adult t-cell leukemia/lymphoma
IL102414A (en) 1991-07-25 1996-08-04 Univ Louisville Res Found Medicinal preparations for the treatment of ocular inflammation, containing rapamycin
US5286730A (en) 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5286731A (en) 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
US5516781A (en) 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5288711A (en) 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
ES2295093T3 (es) 1993-04-23 2008-04-16 Wyeth Conjugados y anticuerpos de rapamicina.
CH686761A5 (de) 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
ES2308955T5 (es) 1993-09-28 2012-04-03 R.P. Scherer Gmbh Fabricación de cápsulas de gelatina blanda
US5561138A (en) 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5496832A (en) 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
FR2736550B1 (fr) 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
GB9606452D0 (en) 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
US7125875B2 (en) * 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
GB0000482D0 (en) 2000-01-11 2000-03-01 Norton Healthcare Ltd Enteric coated pharmaceutical formulation
LT2762140T (lt) 2001-02-19 2017-06-26 Novartis Ag Solidinių smegenų navikų gydymas rapamicino dariniu
CA2446282A1 (en) 2001-05-30 2002-12-05 Novartis Ag 2-{[n-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl]-amino}-alkylboronic acid derivatives
BR0307544A (pt) 2002-02-01 2004-12-07 Ariad Gene Therapeutics Inc Compostos contendo fósforos, componentes e composição bem como, sua utilização através de métodos de tratamentos
DE60324609D1 (de) 2002-09-17 2008-12-18 Wyeth Corp GRANULIERTE FORMULIERUNG DES RAPAMYCINESTERS CCl-779
GB0327840D0 (en) * 2003-12-01 2003-12-31 Novartis Ag Organic compounds
DK1701698T3 (da) 2004-01-08 2008-05-05 Wyeth Corp Direkte komprimerbart farmaceutisk præparat til oral indgivelse af CCI-779
US7405497B2 (en) 2004-04-13 2008-07-29 Electrovaya Inc. Integrated power supply system
GB0504994D0 (en) 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
DE102005017313A1 (de) 2005-04-14 2006-10-19 Volkswagen Ag Verfahren zur Darstellung von Informationen in einem Verkehrsmittel und Kombiinstrument für ein Kraftfahrzeug

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080975A1 (en) * 2001-04-06 2002-10-17 Wyeth Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil
US20050119288A1 (en) * 2003-08-18 2005-06-02 Pfizer Inc Dosing schedule for a novel anticancer agent
WO2006039414A2 (en) * 2004-09-30 2006-04-13 Ariad Gene Therapeutics, Inc. Treatment method
US20060183766A1 (en) * 2005-02-15 2006-08-17 Wyeth Orally bioavailable CCI-779 formulations
US20070105887A1 (en) * 2005-11-04 2007-05-10 Wyeth Antineoplastic combinations of temsirolimus and sunitinib malate

Also Published As

Publication number Publication date
US20070185150A1 (en) 2007-08-09
CN102579467A (zh) 2012-07-18
WO2007059106A3 (en) 2008-06-05
EP2662082A1 (en) 2013-11-13
EP1962839A4 (en) 2010-08-25
CN101360495B (zh) 2012-03-14
IL191356A0 (en) 2009-08-03
AU2006315512A1 (en) 2007-05-24
AU2006315512B2 (en) 2012-11-01
CN101360495A (zh) 2009-02-04
CA2629714A1 (en) 2007-05-24
EP1962839A2 (en) 2008-09-03
JP2014012721A (ja) 2014-01-23
JP5709354B2 (ja) 2015-04-30
JP2009515901A (ja) 2009-04-16
WO2007059106A2 (en) 2007-05-24
EA200801309A1 (ru) 2008-10-30

Similar Documents

Publication Publication Date Title
AU2006315512B2 (en) Administration of an mTOR inhibitor to treat patients with cancer
RU2605335C2 (ru) Комбинированная терапия противоопухолевым алкалоидом
US20230398119A1 (en) Combination therapy involving diaryl macrocyclic compounds
US20100266590A1 (en) Combination therapy
CN108025076A (zh) 使用阿吡莫德治疗癌症的方法
CN118078810A (zh) 用于抑制肿瘤生长的材料和方法
TW201924720A (zh) Ｐａｒｐ抑制劑用於治療化療耐藥的卵巢癌或乳腺癌的用途
US11419862B2 (en) Quinoline derivative for treatment of nasopharyngeal carcinoma
EA007530B1 (ru) Противоопухолевые комбинации
WO2016188399A1 (en) Pharmaceutical compositions and use thereof
CN116159062A (zh) 药物组合物及其用途
US20230321104A1 (en) Use of pyrido[1,2-a]pyrimidinone compound in treating peripheral t cell lymphoma
CA3135916C (en) COMBINED USE OF THE COMPOUND MEDICINE A-NOR-5A ANDROSTANE AND AN ANTI-CANCER MEDICINE
RU2678103C2 (ru) Противоопухолевое средство, содержащее противоопухолевый комплекс платины, и усилитель противоопухолевого эффекта
CN119894514A (zh) 药物组合物及其用途
CN102648911B (zh) 用在靶向治疗的敏化剂、医药组合物、试剂盒及用途
TW201235038A (en) Sensitizer, kit and use for cancer therapy
Koyama The current status of chemotherapy for gastric cancer in Japan with special emphasis on mitomycin C
HK1173387A (en) Use of a rapamycin derivative for the treatment of cancer
WO2025056747A1 (en) Combination of a wee1 inhibitor and a pkmyt1 inhibitor
TW202535398A (zh) 用於治療癌症之包含光學活性氮雜雙環衍生物之醫藥
CN121550252A (zh) 双二羧酸二氨络铂抗癌药物
HK1118704A1 (en) Radiotherapy enhancer

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU